Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo.

Anyovi, Folly; Sabi, Akomola K.; Amekoudi, Yoan Y.; Tsevi, Mawufemo C.; Soliman, Reham; Charles, Pardessus; Karou, Simplice; Simpore, Jacques; Gamal, Shiha

doi:10.21608/mjvh.2021.193441

Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo.

Document Type : Original article

Authors

¹ Laboratory of Molecular Biology and Genetics (LABIOGENE), UFR-SVT, Joseph KI-ZERBO University, Ouagadougou, Burkina Faso.

² Pietro Annigoni Biomolecular Research Center (CERBA), 01 BP 364 Ouagadougou 01, Burkina Faso.

³ Ecole Supérieure des Techniques Biologiques et Alimentaires (ESTBA), Université de Lomé-Togo.

⁴ CHU Sylvanus Olympio, Service de Néphrologie-Hemodialyse,

⁵ Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt

⁶ Tropical Medicine Department, Faculty of Medicine, Port Said University, Egypt

⁷ Faculté des sciences de la Santé, Université de Lomé.

⁸ Ecole Supérieure des Techniques Biologiques et Alimentaires (ESTBA), Université de Lomé-Togo

⁹ Internal Medicine dept., Mansoura Univ., Egypt

¹⁰ Egyptian Liver Research Institute and Hospital (ELRIH), Sherbin, El-Mansoura, Egypt.

10.21608/mjvh.2021.193441

Abstract

Background: The prevalence of hepatitis B surface antigen (HBsAg) and anti-HCV infection (anti-HCV) among hemodialysis patients (HD) varies from country to country and from one center to another. This cross-sectional study was conducted to investigate seroprevalence and associated risk factors for HBsAg and anti-HCV markers among hemodialysis patients in S.O. CHU in Lomé.
Materials and methods: Structured questionnaires were used to obtain socio-demographic data and sera were tested for HBsAg and anti-HCV among End Stage Renal Disease (ESRD) patients undergoing hemodialysis in S.O. CHU in Lomé. Results: Out of 75 patients enrolled in the study, HBsAg and anti-HCV were detected in 6 (8%) and 11 (14.7%) patients respectively. Anti-HCV and HBsAg seropositivity were not associated with the hemodialysis session (p = 0.88) and (p = 0.91) respectively. Furthermore, Univariate analysis showed that, sex, tatoo before dialysis and a history of surgery were not a significant risk factors for HBsAg and HCV seropositivity. The follow-up of the ALT in the both patients (HCV and HBsAg) showed very high significant variation (p = 0.000) and (p = 0.02) respectively. Conclusion: Prevalence of HBsAg and anti-HCV in hemodialysis patients seems low in Lomé. It is recommended to check the patients for HBsAg and anti-HCV before admission to the centers.

Keywords